Name: Doramapimod (BIRB 796)
Brand: Selleck Chemicals
SKU: S1574
Rating: 5 (93 reviews)

Doramapimod (BIRB 796) Chemical Structure

CAS No. 285983-48-4

Selleck's Doramapimod (BIRB 796) has been cited by 93 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Related Compound Libraries

Other p38 MAPK Products

Download Inhibitor Catalog

p38 MAPK Signaling Pathway Map

Biological Activity

Description

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features

The first p38 MAPK inhibitor to be tested in a phase III clinical trial.

Targets

JNK2 ^[1] ()	c-RAF ^[1] ()	Fyn ^[1] ()	p38α ^[1] (Cell-free assay)	p38α ^[7] ()
			0.1 nM(Kd)	38 nM

In vitro

BIRB 796 shows no significant inhibition to ERK-1, SYK, IKK2β, ZAP-70, EGF receptor kinase, HER2, protein kinase A (PKA), PKC, PKC-α, PKC-β (I and II) and PKC-γ. BIRB 796 greatly improves binding affinity by forming a hydrogen bond between the morpholine oxygen and the ATP-binding domain of p38α. BIRB 796 represents one of the most potent and slowest dissociating inhibitors against human p38 MAP kinase now known. ^[1] BIRB 796 potently inhibits c-Raf-1 and Jnk2α2 with IC50 of 1.4 and 0.1 nM, respectively. ^[2] BIRB796 also inhibits the activity and the activation of SAPK3/p38γ at a higher concentration than it does in p38α. BIRB796 blocks the stress-induced phosphorylation of the scaffold protein SAP97, which is a physiological substrate of SAPK3/p38γ. BIRB796 blocks JNK1/2 activation and activity in HEK293 cells, while not inhibits the activation and activity of ERK1/ERK2 in Hela cells. Moreover, the binding of BIRB796 to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4 rather than enhancing their dephosphorylation. ^[3] BIRB 796 blocks baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. BIRB 796 downregulates IL-6 and VEGF secretion in BMSCs triggered by TNF-α and TGF-β1. ^[4] BIRB-796 has a pyrazole scaffold that places a lipophilic t-butyl group into the lower selectivity site and a tolyl ring into the upper selectivity site. BIRB-796 also inhibits B-Raf and Abl with IC50 of 83 nM and 14.6 μM, respectively. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

HOP-92	M4qyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml3QTWM2OD1{ND6zPFM5KM7:TR?=	NG\1d\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
NCI-H2228	NYLNWoZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4KwfmlEPTB;MkOuOlY3QCEQvF2=	M2foUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
CAPAN-1	NVPaWYQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVHJR\|UxRTJ{LkG4PFQh\|ryP	NYPLTlBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
SK-MEL-1	NXLSO3ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWr3eXRvUUN3ME2yNE4{Pjh\|IN88US=>	M{\CVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
DB	NIHob\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFnGRYpKSzVyPUG4Mlc6OjNizszN	NWq0N4VCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
AN3-CA	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV3WbW5VUUN3ME2xPE4yKM7:TR?=	M3LGNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
EW-13	NXnlTJlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn3jTWM2OD1zNz65OVE3KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
LC-2-ad	M3XWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoDCTWM2OD1zNz60N\|Y3KM7:TR?=	NF36NXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
ES8	NID5UnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH7pVXhKSzVyPUG3MlE3PyEQvF2=	M2nWNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NCI-H1581	MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXzJR\|UxRTF5LkC0OFch\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
HMV-II	NX71Um1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVThWnhkUUN3ME2xOE4zOzB7IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
BEN	NHHLeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYDJR\|UxRTF\|LkGyOlQh\|ryP	NG\HcVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
NBsusSR	M1HSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUPJR\|UxRTFyLkiyN\|Uh\|ryP	M{[0clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
MS-1	NITVSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlLZTWM2OD1zMD64NlM2KM7:TR?=	NGXQZ2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
BFTC-905	NXvKWZpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoTmTWM2OD1zMD6xNlM{KM7:TR?=	M2fJNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NCI-SNU-1	NXjJfFdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX7JR\|UxRTlwME[3N\|kh\|ryP	M4PUSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
MPP-89	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXHJR\|UxRThwNE[yOVEh\|ryP	NVSyTlRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
T-24	NEDYfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3vUTmlEPTB;OD60NFY4OyEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
KP-N-YN	NUnMbXNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2XzbmlEPTB;OD6yNFE6KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
IST-MES1	M3fhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1KwWGlEPTB;Nz65OVY{PyEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NCI-H358	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVnJR\|UxRTdwNUO4JO69VQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
GOTO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnX0TWM2OD14LkO5NVYyKM7:TR?=	M360SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
DU-145	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3m2dWlEPTB;Mz65N\|gyOSEQvF2=	Mlz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
EoL-1-cell	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnvZTWM2OD1yLkO0O\|Y{KM7:TR?=	NI\ZV2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
KYSE-270	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX7JR\|UxRTJ2LkW1O\|Mh\|ryP	NEjtepY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
HCC1806	Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{O0bmlEPTB;MkSuO\|c6QSEQvF2=	NFnReoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
HuO-3N1	NVPXXZJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWrJR\|UxRTJ3LkixPFUh\|ryP	M3roWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
HOS	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlfHTWM2OD1{NT65NlkzKM7:TR?=	MlvEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KYSE-510	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1nje2lEPTB;Mk[uNVYyOiEQvF2=	NFnSXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
COLO-741	NIjXUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIn5SGxKSzVyPUK2MlM{OjlizszN	MkjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
H-EMC-SS	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{jVWGlEPTB;Mk[uPVI1PSEQvF2=	NGC3XXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
HCC1937	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWrJR\|UxRTJ5LkKyN\|gh\|ryP	NXHDUllrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
NCI-H2126	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlXjTWM2OD1{Nz6zPVc2KM7:TR?=	NHXvS\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
NCI-H1703	NUC2O3k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MonqTWM2OD1{OD6wOFE{KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
U-2-OS	M3PPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXTJR\|UxRTJ6LkW1NVUh\|ryP	MlPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
DBTRG-05MG	NXX0S4RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYK3dVM5UUN3ME2yPE42PjVzIN88US=>	MmGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
MHH-ES-1	M3\QR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M13ISGlEPTB;M{GuPVQyKM7:TR?=	MlzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HCC1419	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWTXbIFxUUN3ME2zNk4yOTF7IN88US=>	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HOP-62	M2LkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlTOTWM2OD1\|Mj6yO\|AyKM7:TR?=	MlnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
AM-38	NFjmSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmnLTWM2OD1\|Mj65PVMyKM7:TR?=	MmTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NCI-H2009	MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFzmSpZKSzVyPUOzMlQxODdizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
EM-2	NEjoco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkHHTWM2OD1\|Mz61OVEyKM7:TR?=	NUPIeIJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
SW1116	M4i2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFuxSG1KSzVyPUO0MlQ5OzhizszN	NUX3dnlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
SK-N-AS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvMTWM2OD1\|NT6wO\|E1KM7:TR?=	NHX2b\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
ChaGo-K-1	NYCy[nFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVTJR\|UxRTN3Lk[wN\|Ih\|ryP	NF\qWm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK\|5USU6JRWK8M4E,
RT-112	M1K3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M33sS2lEPTB;M{WuPVg4QSEQvF2=	NWOzTGJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
HTC-C3	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4HIbmlEPTB;M{[uNlM2PSEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
SK-NEP-1	NUO5cHRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF72eXFKSzVyPUO2MlYyODZizszN	NYjjbnBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
LB831-BLC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVzJR\|UxRTN5Lk[1OFEh\|ryP	MnX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
CTB-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWLqemVyUUN3ME2zPE41PTF{IN88US=>	MoixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
MOLT-4	NGn5U5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3r0fmlEPTB;M{iuPFM6OSEQvF2=	NUnNco84RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
SW756	M3TyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkTXTWM2OD12MD65N\|g2KM7:TR?=	MoLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
CAL-72	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXLxTpNEUUN3ME20Nk4xOyEQvF2=	NVzTWIk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
KNS-62	NF;aVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoLsTWM2OD12Mj62Nlk3KM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
KARPAS-299	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEnTV3NKSzVyPUSzMlMzOzNizszN	MljpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HEL	NVLWeVNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX3JR\|UxRTR3LkS2OFYh\|ryP	NXz2W3ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
KP-4	NXP3ZmM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIG0UlVKSzVyPUS2Mlc{PjFizszN	NYHvTJpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
NEC8	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHHMcYRKSzVyPUS3MlE3PjFizszN	NYqzd3lSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB\|Nk[3M{c,W0GQR1XSQE9iRg>?
G-402	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mlq2TWM2OD12OD63NFEzKM7:TR?=	MnznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
Sf21	NYrHfml6TnWwY4Tpc44h[XO\|YYm=		MV;CbY5lcW6pIHHm[olvcXS7IITvJJdqdGRidInw[UBpfW2jbjDibY91cW5ibHHi[Yxt\WRicEO4JIFteGijIDi5JJRwKDN3MjDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKHOoMkGgbY5{\WO2IHPlcIx{KFOSUjDhcoFtgXOrczygT4QhRSByLkCwNFEzOyEQvF2u	NFW1Znc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOFQ{OSd-Mki4N\|Q1OzF:L3G+
THP1	MoKySpVv[3Srb36gZZN{[Xl?		MXHJcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIGTOSoFteGijIIDyc4R2[3Srb36gbY4hcHWvYX6gWGhROSClZXzsd{whUUN3MDC9JFAvODF\|IN88UU4>	Mn;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MkW3OlgoRjF6M{K1O\|Y5RC:jPh?=
U937	NWrXdJh5SW62aXnu[oxidW2jdH;yfUBie3OjeR?=	NHr1d\|AzKGi{cx?=	NHPLbItCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKGSrZn\ldoVvfGmjdHXkJIh2dWGwIGW5N\|ch[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhVFCVLYP0bY12dGG2aX;uJIZweiB2IHjyd{BjgSC\|YX7ke4lkcCCHTFnTRUBz\WyjdHn2[UB1dyC4ZXjpZ4xmNXS{ZXH0[YQh[2:wdILvcEwhUUN3MDC9JFAvODF3IN88UU4>	M{nnfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OECwN\|A6Lz5{NkiwNFMxQTxxYU6=
THP1	MkT4SpVv[3Srb36gZZN{[Xl?		MnHpTY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDUUmZidHCqYTDwdo9lfWO2aX;uJIlvKGi3bXHuJHRJWDFiY3XscJMtKEmFNUCgQUAxNjBzODFOwG0v	NHXtfZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO1OlkzQSd-MUmzOVY6Ojl:L3G+
THP1	MWXGeY5kfGmxbjDhd5NigQ>?		NUXLWllZUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EB1fW2xcjDu[YNzd3OrczDmZYN1d3JvYXzwbIEhMFSQRj3hcJBp[SlicILv[JVkfGmxbjDpckBVUFBvMTDj[YxteyxiRVO1NEA:KDBwMEG4JO69VS5?	NIT2bY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkC4OlQ5PSd-MUKwPFY1QDV:L3G+
THP	NYW0SWlTTnWwY4Tpc44h[XO\|YYm=		M1rDb3Rme3SnZDDmc5IhcW6qaXLpeIlwdiCxZjDUeY1weiCwZXPyc5NqeyCoYXP0c5ItKGGucHjhJIlvKFSKUDDj[YxteyxiRVO1NEA:KDBwMEG4JO69VS5?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV4MUC4O{c,OTR3NkGwPFc9N2F-
THP1	MlO4SpVv[3Srb36gZZN{[Xl?		MlnUTY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDUUmZidHCqYTDwdo9lfWO2aX;uJIlvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkCxPEDPxE1w	M2HsNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[wNVA5Lz5zN{W2NFExQDxxYU6=
THP1	M2\Vc2Z2dmO2aX;uJIF{e2G7		NXrHbXR4UW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIHnuJIh2dWGwIGTIVFEh[2WubIOsJGlEPTBiPTCwMlAyQCEQvF2u	MoS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NkK5OFAoRjF6NE[yPVQxRC:jPh?=
HLF	MmqySpVv[3Srb36gZZN{[Xl?		M17iS2lvcGmkaYTpc44hd2ZicEO4ZYxxcGFicHjvd5Bpd3K7bHH0bY9vKGmwIFnMMVEu[WyyaHGtd5RqdXWuYYTl[EBJVEZiY3XscJMtKEmFNUCgQUAxNjB2NzFOwG0v	NHjTUoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[wNlI3Oid-MUi2NFIzPjJ:L3G+
HLF	MW\GeY5kfGmxbjDhd5NigQ>?		Mk[5TY5pcWKrdHnvckBw\iCKU2CyO{BxcG:\|cHjvdplt[XSrb36gbY4hUUxvMT3hcJBp[S2\|dHnteYxifGWmIFjMSkBk\WyuczygTWM2OCB;IECuNFU5KM7:TT6=	M2X2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkCyNlYzLz5zOE[wNlI3OjxxYU6=
HEK293F	NFrW[o9HfW6ldHnvckBie3OjeR?=		MnzUTY5pcWKrdHnvckBw\iC\|b3TpeY0h[XK\|ZX7heIUh[WO2aY\heIVlKE5vdHXycYlv[WxiR2PUMZRi\2enZDDCdpVocWFibXHsZZlqKE2SS{Gg[ZhxemW\|c3XkJIlvKEiHS{K5N2Yh[2WubIOgeZNqdmdiRlHNMZA{QHSrZHWgZZMhe3Wkc4TyZZRmKGK7IFnNRXAh[XO\|YYmsJGlEPTBiPTCwMlE1KM7:TT6=	M2TpSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|YzLz5{OUW0NVM3OjxxYU6=
BL21(DE3)	M1yxTWZ2dmO2aX;uJIF{e2G7		M4TSemlvcGmkaYTpc44hd2ZicEO4ZYxxcGFiYXP0bZZmKG[xcn2g[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhSkx{MTjESVMqKGOnbHzzJIJ6KEiWUl[gZZN{[XluIFnDOVAhRSByLkK1JO69VS5?	NY\NNld7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5Nlg5PThpPkG5PVI5QDV6PD;hQi=>
whole blood cells	NIXYT\|NCdnSraX7mcIFudWG2b4L5JIF{e2G7	M3j5OlQhcHK\|	MXfBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIIfoc4xmKGKub3;kJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBi\nSncjC0JIhzeyCkeTD0bY1mNXKnc3;seoVlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwNjFOwG0v	NHjXT\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0PVI5Oid-MkK3OFkzQDJ:L3G+
A673	MX;xTHRUKGG\|c3H5		NV;JZnpIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NEXac5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NXrrNnFseUiWUzDhd5NigQ>?		NUG1OpB3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NILLSGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MVjxTHRUKGG\|c3H5		MmTldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NWPWbHI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NXO3XI16eUiWUzDhd5NigQ>?		NHjsWGhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NHm0b\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	M4nVfZFJXFNiYYPzZZk>		NVfYclc3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MWPxTHRUKGG\|c3H5		NGSxU3ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	Ml\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MkjEdWhVWyCjc4PhfS=>		MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NV;DUJcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot

p-p38 / p38 ; mTOR / p-S6K / S6K / p-MK2 / MK2 / p-Hsp27 / Hsp27 ; p-p38 / γ-H2AX

23349819 26844273 27082306

In vivo

BIRB 796 (30 mg/kg) inhibits 84% of TNF-α in LPS-stimulated mice and demonstrates efficacy in a mouse model of established collagen-induced arthritis. ^[1] BIRB 796 has good pharmacokinetic performance even after oral administration in mice. ^[2]

Protocol (from reference)

Animal Research: ^[2]	Animal Models: Collagen-induced arthritis in female Balb/c mice Dosages: 1 mg/kg (intravenous) or 10 mg/kg (oral) Administration: Intravenous injection or by oral (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (189.51 mM)
	Ethanol	100 mg/mL (189.51 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+40%PEG300+5%Tween80 +50%H2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	527.66
Formula	C₃₁H₃₇N₅O₃
CAS No.	285983-48-4
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5

Download Doramapimod (BIRB 796) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02211885	Completed	Drug: 14C-BIRB 796 BS	Healthy	Boehringer Ingelheim	October 2002	Phase 1

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):